Portola Pharmaceuticals   Print Page    Close Window

Corporate Profile

Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s two FDA-approved medicines are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for... Read More

Stock Quote
NASDAQ PTLA (Common Stock)
$30.15 + 0.20
Stock chart for: PTLA.O.  Currently trading at $30.15 with a 52 week high of $46.50 and a 52 week low of $14.81.
02/21/19 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Upcoming EventsMore >>
Q4 2018 Portola Pharmaceuticals, Inc. Financial Results Conference Call
Friday, March 1, 2019 8:30 a.m. ET

Archived Events
JP Morgan Corporate Update
Tuesday, January 8, 2019 10:00 a.m. ET
Supporting Materials
Download Event Supporting Material Presentation

Portola Pharmaceuticals, Inc. at the Citi’s Global Healthcare Conference
Thursday, December 6, 2018
LocationNew York, NY